Top ten stories in the pharmaceutical industry this week
pharmafile | September 2, 2016 | News story | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | pharmafile.com, top ten
As Mylan is left reeling from the backlash on its EpiPen price increase in the US, many lost their jobs as refocusing and restructuring affected many. Here’s the top ten stories on Pharmafile.com this week:
10. FDA approves Novartis Enbrel biosimilar
This is the first biosimilar for the inflammatory disease drug to be approved in the US
9. Cipla receives FDA approval for generic version of Valeant antidepressant
Indian pharma and biotech company’s generic bupropion hydrochloride extended release tablets get the go-ahead in the US
8. The September issue of Pharmafocus is now live!
Check out the latest news in the industry, plus special features on Brexit, cloud computing and trial transparency
7. AstraZeneca to pay £5.52 million to settle bribery probe
SEC accuses Chinese and Russian subsidiaries of wilful misconduct in influencing government officials and fraudulent accounting
6. EMA accepts regulatory submission for proposed Herceptin biosimilar
Mylan and Biocon believe that the strength of its data on the bioequivalence compared with the originator will be enough to secure an approval
5. Jobs to go at Takeda as it shuts down Cambridge facility
Takeda had occupied the site at the Cambridge Science Park since 2007
4. Teva to lay off 236 in Pomona, New York
All employees are to be laid off in the run-up to the facility’s closure in February.
3. KaloBios cuts ties with former CEO Martin Shkreli, outlines ‘maniacal’ turnaround plan
Shkreli is no longer a stakeholder as he sells all of his remaining shares for $6 million.
2. Up to 120 jobs set to go as Novartis closes down Cell and Gene Therapies unit
The company confirmed that it will integrate its operations into the broader organisation.
1. Sanofi & Regeneron’s Praluent cholesterol treatment smashes Phase III target
93% of participants experienced at least a 50% reduction in the need for cholesterol-removing procedures in the Phase III trial.
Related Content
Top Ten most popular articles on Pharmafile.com this week
As the year winds to a close, excitement is rising around the efficacy and availability …
Top Ten most popular articles on Pharmafile.com this week
The top ten news stories this week focus on herd immunity, as the Director of …
Pharmafile.com’s weekly COVID-19 news round-up
The coronavirus news this week focuses on the development of treatments to alleviate symptoms of …
